272 related articles for article (PubMed ID: 15993594)
21. [Cyclopentadienyl]metalcarbonyl complexes of acetylsalicylic acid as neo-anticancer agents.
Rubner G; Bensdorf K; Wellner A; Bergemann S; Ott I; Gust R
Eur J Med Chem; 2010 Nov; 45(11):5157-63. PubMed ID: 20828891
[TBL] [Abstract][Full Text] [Related]
22. COX-2 inhibition as a tool to treat and prevent colorectal cancer.
Tuynman JB; Peppelenbosch MP; Richel DJ
Crit Rev Oncol Hematol; 2004 Nov; 52(2):81-101. PubMed ID: 15501074
[TBL] [Abstract][Full Text] [Related]
23. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
Mohseni H; Zaslau S; McFadden D; Riggs DR; Jackson BJ; Kandzari S
J Surg Res; 2004 Jun; 119(2):138-42. PubMed ID: 15145695
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of cyclooxygenase (COX) enzymes by compounds from Daucus carota L. Seeds.
Momin RA; De Witt DL; Nair MG
Phytother Res; 2003 Sep; 17(8):976-9. PubMed ID: 13680840
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells.
Ferrera P; Arias C
Neurochem Int; 2005 Dec; 47(8):589-96. PubMed ID: 16169124
[TBL] [Abstract][Full Text] [Related]
26. Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action.
Ott I; Schmidt K; Kircher B; Schumacher P; Wiglenda T; Gust R
J Med Chem; 2005 Jan; 48(2):622-9. PubMed ID: 15658875
[TBL] [Abstract][Full Text] [Related]
27. Quantitative structure activity relationship studies of diaryl furanones as selective COX-2 inhibitors.
Shahapurkar S; Pandya T; Kawathekar N; Chaturvedi SC
Eur J Med Chem; 2004 Apr; 39(4):383-8. PubMed ID: 15072847
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Vona-Davis L; Riggs DR; Jackson BJ; McFadden DW
J Surg Res; 2004 Jun; 119(2):143-8. PubMed ID: 15145696
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of subtype-selective cyclooxygenase (COX) inhibitors derived from thalidomide.
Sano H; Noguchi T; Tanatani A; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2005 May; 13(9):3079-91. PubMed ID: 15809144
[TBL] [Abstract][Full Text] [Related]
30. 5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents.
Ottanà R; Maccari R; Barreca ML; Bruno G; Rotondo A; Rossi A; Chiricosta G; Di Paola R; Sautebin L; Cuzzocrea S; Vigorita MG
Bioorg Med Chem; 2005 Jul; 13(13):4243-52. PubMed ID: 15905093
[TBL] [Abstract][Full Text] [Related]
31. 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
Ranatunge RR; Earl RA; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Schwalb DJ; Young DV; Zemtseva IS
Bioorg Med Chem Lett; 2004 Dec; 14(24):6049-52. PubMed ID: 15546727
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of 2-substituted-1-naphthol derivatives on cyclooxygenase I and II.
Kongkathip B; Sangma C; Kirtikara K; Luangkamin S; Hasitapan K; Jongkon N; Hannongbua S; Kongkathip N
Bioorg Med Chem; 2005 Mar; 13(6):2167-75. PubMed ID: 15727869
[TBL] [Abstract][Full Text] [Related]
33. Role of COX-2 selective inhibitors for prevention and treatment of cancer.
Amir M; Agarwal HK
Pharmazie; 2005 Aug; 60(8):563-70. PubMed ID: 16124396
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro.
Farivar-Mohseni H; Kandzari SJ; Zaslau S; Riggs DR; Jackson BJ; McFadden DW
Am J Surg; 2004 Nov; 188(5):505-10. PubMed ID: 15546559
[TBL] [Abstract][Full Text] [Related]
35. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
Kim SH; Kim SH; Song YC; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():635-41. PubMed ID: 19723114
[TBL] [Abstract][Full Text] [Related]
36. 2, 3-Diaryl-5-ethylsulfanylmethyltetrahydrofurans as a new class of COX-2 inhibitors and cytotoxic agents.
Singh P; Mittal A; Kaur S; Holzer W; Kumar S
Org Biomol Chem; 2008 Aug; 6(15):2706-12. PubMed ID: 18633528
[TBL] [Abstract][Full Text] [Related]
37. NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines.
Tesei A; Ricotti L; Ulivi P; Medri L; Amadori D; Zoli W
Int J Oncol; 2003 Jun; 22(6):1297-302. PubMed ID: 12738997
[TBL] [Abstract][Full Text] [Related]
38. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Wagner M; Loos J; Weksler N; Gantner M; Corless CL; Barry JM; Beer TM; Garzotto M
Biochem Biophys Res Commun; 2005 Jul; 332(3):800-7. PubMed ID: 15907789
[TBL] [Abstract][Full Text] [Related]
39. In vitro inhibitory effects of thymol and quinones of Nigella sativa seeds on cyclooxygenase-1- and -2-catalyzed prostaglandin E2 biosyntheses.
Marsik P; Kokoska L; Landa P; Nepovim A; Soudek P; Vanek T
Planta Med; 2005 Aug; 71(8):739-42. PubMed ID: 16142638
[TBL] [Abstract][Full Text] [Related]
40. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis.
Peng G; Dixon DA; Muga SJ; Smith TJ; Wargovich MJ
Mol Carcinog; 2006 May; 45(5):309-19. PubMed ID: 16508969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]